isotretinoin

FDA Drug Profile — Absorica LD, Absorica, Amnesteem

isotretinoin is listed in the FDA National Drug Code directory with 47 NDC codes, marketed under brand names including Absorica LD, Absorica, Amnesteem. Available dosage forms: capsule, capsule, liquid filled.

Drug details

Generic Name
isotretinoin
Brand Names
Absorica LD, Absorica, Amnesteem
Application Number
NDA211913
Sponsor
Sun Pharmaceutical Industries, Inc.
NDC Codes
47
Dosage Forms
CAPSULE, CAPSULE, LIQUID FILLED
Routes
ORAL
Active Ingredients
ISOTRETINOIN

Indications and Usage

1 INDICATIONS AND USAGE Isotretinoin Capsules is indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Isotretinoin Capsules is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use : If a second course of Isotretinoin Capsules treatment is needed, it is not recommended before a two-month waiting period because the patient's acne may continue to improve following a 15 to 20-week course of treatment [see Dosage and Administration (2.2)]. Isotretinoin Capsules is a retinoid indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Isotretinoin Capsules are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. (1) Limitations of Use : If a second course of Isotretinoin Capsules treatment is needed, it is not recommended before a two-month waiting period because the patient's acne may continue to improve following a 15 to 20-week course of treatment. (1)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.